Summary:
- Pfizer, a major pharmaceutical company, has entered into an exclusive licensing agreement with 3SBio, a biopharmaceutical company.
- The agreement allows Pfizer to develop and commercialize 3SBio's novel biologic drug candidate for the treatment of certain autoimmune and inflammatory diseases.
- This collaboration aims to expand Pfizer's pipeline of innovative therapies and provide new treatment options for patients suffering from these types of conditions.